Hybrid Closed Loop Pivotal Trial in Type 1 Diabetes

Description

This study is a single-arm, multi-center, Home and Hotel Clinical Investigation in subjects with type 1 diabetes on insulin pump therapy. The purpose of this study is to demonstrate that the closed loop algorithm that is built into the 670G insulin pump is safe as part of the overall system.

Study Start Date

June 2015

Estimated Completion Date

May 2016

Interventions

  • Device: Insulin Pump
  • Other: Blood Glucose Meter testing
  • Other: i-STAT blood testing

Specialties

  • Internal Medicine: Endocrinology
  • Nursing: Endocrinology
  • Endocrinology: Diabetes
  • Physician Assistant: Endocrinology

MeSH Terms

  • Diabetes Mellitus, Type 1
  • Endocrine System Diseases
  • Immune System Diseases

Study ID

Medtronic Diabetes -- CEP 294

Status

Unknown

Trial ID

NCT02463097

Study Type

Interventional

Trial Phase

Phase 3

Enrollment Quota

150

Sponsor

Medtronic Diabetes

Inclusion Criteria

    1. Is age 14
  • 75 years at time of screening 2. Has a clinical diagnosis of type 1 diabetes for 2 years or more as determined via medical record or source documentation by an individual qualified to make a medical diagnosis 3. Is willing to participate in a hotel study for the specified duration of hotel stay. 4. Must have companion who will sleep in the same dwelling place every night during the study period and should also be able to call the subject daily in the event the subject is traveling. 5. Is willing to perform ? 4 finger stick blood glucose measurements daily 6. Is willing to perform required sensor calibrations 7. Is willing to wear the system continuously throughout the study 8. Has a Glycosylated hemoglobin (A1C) value less than 10.0% (as processed by Central Lab) at time of screening visit 9. Has TSH in the normal range OR if the TSH is out of normal reference range the Free T3 is below or within the lab's reference range and Free T4 is within the normal reference range. 10. Pump therapy for greater than 6 months prior to screening (with or without CGM experience) 11. Is willing to upload data from the study pump, must have Internet access and a computer system that meets the requirements for uploading the study pump 12. If subject has celiac disease, it has been adequately treated as determined by the investigator 13. Is willing to take one of the following insulins and can financially support the use of either of the 2 insulin preparations throughout the course of the study (i.e. co-payments for insulin with insurance or able to pay full amount)
  • Humalog┬« (insulin lispro injection)
  • NovoLog┬« (insulin aspart) 14. With history of cardiovascular event 1 year or more from the time of screening must have an EKG within 6 months prior to screening or during screening. If subject has an abnormal EKG, participation is allowed if there is clearance from a cardiologist 15. With 3 or more cardiovascular risk factors listed below must have an EKG within 6 months prior to screening or during screening. If subject has an abnormal EKG, participation is allowed if there is clearance from a cardiologist a. Cardiovascular risk factors include:
  • Age >35 years
  • Type 1 diabetes of >15 years' duration
  • Presence of any additional risk factor for coronary artery disease
  • Presence of microvascular disease (proliferative retinopathy or nephropathy, including microalbuminuria)
  • Presence of peripheral vascular disease
  • Presence of autonomic neuropathy 16. With history of cardiovascular event 1 year or more from the time of screening must have a stress test within 6 months prior to screening or during run in period. If subject fails stress test, participation is allowed if there is clearance from a cardiologist 17. Must be able to speak and be literate in English

Exclusion Criteria

    1. Has a history of 2 or more episodes of severe hypoglycemia, which resulted in any the following during the 6 months prior to screening: 1. Medical assistance (i.e. Paramedics, Emergency Room ( ER) or Hospitalization) 2. Coma 3. Seizures 2. Is unable to tolerate tape adhesive in the area of sensor placement 3. Has any unresolved adverse skin condition in the area of sensor placement (e.g., psoriasis, dermatitis herpetiformis, rash, Staphylococcus infection) 4. Females who are sexually active and able to conceive will be excluded if they are not using an effective method of contraception and do not agree to continue using an effective method of contraception for the duration of the study as determined by investigator. 5. Has had any of the following cardiovascular events within 1 year of screening: myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, ventricular rhythm disturbances or thromboembolic disease 6. Is being treated for hyperthyroidism at time of screening 7. Has diagnosis of adrenal insufficiency 8. Has had DKA in the 6 months prior to screening visit. 9. Has taken any oral, injectable, or intravenous (IV) steroids within 8 weeks from time of screening visit, or plans to take any oral, injectable, or IV steroids during the course of the study 10. Actively participating in an investigational study (drug or device) wherein he/she has received treatment from an investigational study drug or investigational study device in the last 2 weeks 11. Has been hospitalized or has visited the ER in the 6 months prior to screening resulting in a primary diagnosis of uncontrolled diabetes 12. Currently abusing illicit drugs 13. Currently abusing marijuana. 14. Currently abusing prescription drugs 15. Currently abusing alcohol 16. Using pramlintide (Symlin), DPP-4 inhibitor, liraglutide (Victoza or other GLP-1 agonists), metformin, canagliflozin (Invokana or other SGLT2 inhibitors) at time of screening 17. Has a history of visual impairment which would not allow subject to participate in the study and perform all study procedures safely, as determined by the investigator 18. Has elective surgery planned that requires general anesthesia during the course of the study 19. Has a sickle cell disease, hemoglobinopathy or has received red blood cell transfusion or erythropoietin within 3 months prior to time of screening 20. Plans to receive red blood cell transfusion or erythropoietin over the course of study participation 21. Diagnosed with current eating disorder such as anorexia or bulimia 22. Diagnosed with chronic kidney disease that results in chronic anemia 23. Hematocrit that is below the normal reference range of lab used. 24. On dialysis 25. Serum creatinine of >2 mg/dL.

Gender

Both

Ages

14 Years to 75 Years

Accepts Healthy Volunteers

No

Study Locations and Contact Information (9)

Study Location Distance Name Phone Email
Yale University School of Medicine - New Haven, Connecticut 18.1 miles Lori Carria 203-737-3595 Lori.carria@yale.edu
University of Virginia - Charlottesville, Virginia 357.1 miles Mary Oliveri 434-982-0602 MC7M@hscmail.mcc.virginia.edu
Atlanta Diabetes Associates - Atlanta, Georgia 800.8 miles Jennifer Boyd 404-355-4393 jboyd@atlantadiabetes.com
Park Nicollet ClinicInternational Diabetes Center Adult and Pediatric - Minneapolis, Minnesota 1,045.5 miles None None None
Barbara Davis Center for Childhood Diabetes Adult - Aurora, Colorado 1,658.2 miles None None None
Barbara Davis Center for Childhood Diabetes Pediatric - Aurora, Colorado 1,658.2 miles Laurel Messer 303-724-6718 laurel.messer@ucdenver.edu
Rainer Clinical Research Center - Renton, Washington 2,421.8 miles None None None
AMCR Institute - Escondido, California 2,456.0 miles Yvonne Bedolla 760-466-1537 ybedolla@amcrinstitute.com
Stanford University Medical Center - Palo Alto, California 2,594.5 miles None None None

ClinicalTrialsLocator.com provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from ClinicalTrials.gov. This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.